Blair William & Co. IL increased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO – Get Rating) by 1.5% in the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 152,954 shares of the medical research company’s stock after purchasing an additional 2,189 shares during the quarter. Blair William & Co. IL’s holdings in Thermo Fisher Scientific were worth $102,057,000 at the end of the most recent reporting period.
Several other hedge funds have also modified their holdings of TMO. Widmann Financial Services Inc. acquired a new position in shares of Thermo Fisher Scientific in the fourth quarter valued at $26,000. Lee Financial Co bought a new position in Thermo Fisher Scientific in the fourth quarter valued at about $32,000. Costello Asset Management INC bought a new position in Thermo Fisher Scientific in the fourth quarter valued at about $33,000. Cranbrook Wealth Management LLC boosted its holdings in Thermo Fisher Scientific by 43.5% in the third quarter. Cranbrook Wealth Management LLC now owns 66 shares of the medical research company’s stock valued at $38,000 after acquiring an additional 20 shares during the last quarter. Finally, Sumitomo Mitsui Financial Group Inc. lifted its stake in Thermo Fisher Scientific by 141.7% in the fourth quarter. Sumitomo Mitsui Financial Group Inc. now owns 58 shares of the medical research company’s stock valued at $38,000 after buying an additional 34 shares during the period. Institutional investors own 87.48% of the company’s stock.
A number of equities research analysts have recently commented on the company. Zacks Investment Research lowered Thermo Fisher Scientific from a “buy” rating to a “hold” rating and set a $609.00 price target on the stock. in a research report on Monday, January 24th. Barclays started coverage on Thermo Fisher Scientific in a report on Wednesday, January 26th. They set an “overweight” rating and a $700.00 price objective for the company. Wells Fargo & Company downgraded Thermo Fisher Scientific from an “equal weight” rating to an “underweight” rating and decreased their price objective for the stock from $605.00 to $525.00 in a report on Monday, April 25th. StockNews.com started coverage on Thermo Fisher Scientific in a research note on Thursday, March 31st. They issued a “hold” rating for the company. Finally, BTIG Research restated a “buy” rating and issued a $718.00 price target on shares of Thermo Fisher Scientific in a research note on Thursday, February 3rd. One research analyst has rated the stock with a sell rating, three have issued a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $647.00.
Thermo Fisher Scientific (NYSE:TMO – Get Rating) last announced its quarterly earnings data on Thursday, April 28th. The medical research company reported $7.25 earnings per share for the quarter, beating the consensus estimate of $6.17 by $1.08. The firm had revenue of $11.82 billion during the quarter, compared to analysts’ expectations of $10.66 billion. Thermo Fisher Scientific had a return on equity of 25.33% and a net margin of 18.49%. The company’s quarterly revenue was up 19.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $7.21 EPS. On average, equities analysts anticipate that Thermo Fisher Scientific Inc. will post 22.69 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, July 15th. Stockholders of record on Wednesday, June 15th will be issued a dividend of $0.30 per share. The ex-dividend date is Tuesday, June 14th. This represents a $1.20 dividend on an annualized basis and a dividend yield of 0.22%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 6.26%.
In related news, CEO Marc N. Casper sold 2,181 shares of the business’s stock in a transaction on Wednesday, May 4th. The stock was sold at an average price of $562.46, for a total transaction of $1,226,725.26. Following the sale, the chief executive officer now owns 183,373 shares in the company, valued at approximately $103,139,977.58. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction on Monday, May 2nd. The stock was sold at an average price of $545.60, for a total value of $5,456,000.00. Following the sale, the chief executive officer now owns 183,373 shares in the company, valued at approximately $100,048,308.80. The disclosure for this sale can be found here. Insiders have sold a total of 12,381 shares of company stock valued at $6,791,597 in the last three months. 0.43% of the stock is owned by insiders.
About Thermo Fisher Scientific (Get Rating)
Thermo Fisher Scientific Inc offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
- Get a free copy of the StockNews.com research report on Thermo Fisher Scientific (TMO)
- Zoom Video Communications Is Primed To Launch Higher
- Fundamental Strength Makes Williams-Sonoma One for Your Recovery Watchlist
- Institutions Buy The Dip In Petco Health and Wellness Company
- Veeva Systems: Increasing NDR and Other Wins
- Autozone Edges Past Advanced Auto Parts In Q1 2022
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.